Multivalent Porous Silicon Nanoparticles Enhance the Immune Activation Potency of Agonistic CD40 Antibody

被引:71
|
作者
Gu, Luo [1 ]
Ruff, Laura E. [2 ]
Qin, Zhengtao [1 ]
Corr, Maripat [3 ]
Hedrick, Stephen M. [4 ]
Sailor, Michael J. [1 ]
机构
[1] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
CROSS-PRESENTATION; DRUG-DELIVERY; QUANTUM DOTS; CELLS; MICROPARTICLES; IMMUNOTHERAPY; RESPONSES; INTERNALIZATION; DISSOLUTION; INDUCTION;
D O I
10.1002/adma.201200776
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
One of the fundamental paradigms in the use of nanoparticles to treat disease is to evade or suppress the immune system in order to minimize systemic side effects and deliver sufficient nanoparticle quantities to the intended tissues. However, the immune system is the body's most important and effective defense against diseases. It protects the host by identifying and eliminating foreign pathogens as well as self-malignancies. Here we report a nanoparticle engineered to work with the immune system, enhancing the intended activation of antigen presenting cells (APCs). We show that luminescent porous silicon nanoparticles (LPSiNPs), each containing multiple copies of an agonistic antibody (FGK45) to the APC receptor CD40, greatly enhance activation of B cells. The cellular response to the nanoparticle-based stimulators is equivalent to a 30-40 fold larger concentration of free FGK45. The intrinsic near-infrared photoluminescence of LPSiNPs is used to monitor degradation and track the nanoparticles inside APCs.
引用
收藏
页码:3981 / 3987
页数:7
相关论文
共 50 条
  • [41] PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8+ T cells in breast cancer
    Chaib, Mehdi
    Sipe, Laura M. M.
    Yarbro, Johnathan R. R.
    Bohm, Margaret S. S.
    Counts, Brittany R. R.
    Tanveer, Ubaid
    Pingili, Ajeeth K. K.
    Daria, Deidre
    Marion, Tony N. N.
    Carson, James A. A.
    Thomas, Paul G. G.
    Makowski, Liza
    CANCER LETTERS, 2022, 531 : 98 - 108
  • [42] CRISPR/Cas9-targeting of CD40 in hematopoietic stem cells limits immune activation mediated by anti-CD40
    Wang, Rui
    Graham, Sean
    Sun, Ning
    McCarthy, Donna
    Peng, Ruoqi
    Erickson, Jamie
    Oconnor, Liz
    Zhu, Xiaochun
    Wurbel, Marc
    Dunstan, Robert
    Westmoreland, Susan
    Chung, Namjin
    Ghayur, Tariq
    Gu, Jijie
    PLOS ONE, 2020, 15 (03):
  • [43] Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity - From the bench to the bedside and back
    Weitzenfeld, Polina
    Osorio, Juan C.
    Ravetch, Jeffrey V.
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [44] Modulation of the humoral immune response by targeting CD40 and FcγRII/III; delivery of soluble but not particulate antigen to CD40 enhances antibody responses with a Th1 bias
    Szekeres, Zsuzsanna
    Herbath, Melinda
    Szittner, Zoltan
    Papp, Krisztian
    Erdei, Anna
    Prechl, Kizsef
    MOLECULAR IMMUNOLOGY, 2011, 49 (1-2) : 155 - 162
  • [45] CD40 signaling activated by agonistic anti-CD40 monoclonal antibody 5C11 has different effects on biological behavior of gastric carcinoma cells
    Li Rui
    Chen Wei-Chang
    Wang Wei-peng
    Tian Wen-yan
    Zhang Xue-guang
    IMMUNOLOGY LETTERS, 2010, 131 (02) : 120 - 125
  • [46] Balancing efficacy and toxicity of a fibroblast activation protein dependent tetravalent CD40 agonist antibody for cancer therapy
    Chen, Simeng
    Lin, Yuan
    Zhou, Xiaoru
    Sun, Xing
    Yang, Changyong
    Liao, Cheng
    CANCER RESEARCH, 2024, 84 (06)
  • [47] The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity
    Mangsbo, Sara M.
    Broos, Sissela
    Fletcher, Erika
    Veitonmaeki, Niina
    Furebring, Christina
    Dahlen, Eva
    Norlen, Per
    Lindstedt, Malin
    Toetterman, Thomas H.
    Ellmark, Peter
    CLINICAL CANCER RESEARCH, 2015, 21 (05) : 1115 - 1126
  • [48] Phase 1 study to evaluate the safety and tolerability of the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors
    Bendell, Johanna C.
    Fakih, Marwan
    Infante, Jeffrey R.
    Bajor, David Lawrence
    Cristea, Mihaela C.
    Tremblay, Thomas
    Trifan, Ovidiu C.
    Vonderheide, Robert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] CD40 Ligand and GMCSF Coexpression Enhance the Immune Responses and Protective Efficacy of PCV2 Adenovirus Vaccine
    Li, Delong
    Huang, Yong
    Du, Qian
    Wang, Zhenyu
    Chang, Lingling
    Zhao, Xiaomin
    Tong, Dewen
    VIRAL IMMUNOLOGY, 2016, 29 (03) : 148 - 158
  • [50] Phase 1 study to evaluate the safety and tolerability of the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors
    Fakih, Marwan
    Bajor, David
    Mamtani, Ronac
    Tremblay, Thomas
    Trifan, Ovid
    Vonderheide, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5